March/April - West Virginia State Medical Association

Scientific Article |using one of them in addition toribavirin and pigulated interferon.References1.2.3.4.5.6.Williams R. Global challenges in liver disease.Hepatology 2006; 44:521-526.Ghany et al. Diagnosis, management, andtreatment of Hepatitis C: An update. Hepatology2009; 49:1355-1374.Berg T. Tailored treatment for hepatitis C. MDConsult 2010; at www.mdconsult.com/das/article/body/185458161-2/jorg.Ge D, Fellay J, Thompson AJ, et al. Geneticvariation in IL28B predicts hepatitis C treatmentinducedviral clearance, Nature 2009; 461:798-801.Lindahl K, Stahle L, Bruchfeld A, Schvarcz R.High dose ribavirin in combination with standarddose peg-interferon for treatment of patients withchronic hepatitis C. Hepatology 2005; 41:275-279.Jiang D, Guo H, Xu C, et al. Identification ofthree interferon inducible cellular enzymes thatinhibit the replication of hepatitis C virus. J Virol2008; 82:1665.7. Rossignol JF, Kabil SM, El-Gohary Y, et al.Clinical trial: randomized double-blindedplacebo-controlled study of nitazoxanidemonotherapy for the treatment of patients withchronic hepatitis C genotype 4. AlimentPharmacol Ther 2008; 28:574.8. Rossignol JF, Elfert A, El-Gohary Y, Keefe EB.Improved virologic response in chronic hepatitisC genotype 4 treated with nitazoxanide,peginterferon, and ribavirin. Gastroenterology2009; 136:856.9. Salberg M, Frelin L, Diepolder H, et al. A firstclinical trial of therapeutic vaccination usingnaked DNA delivered in vivo electroporationshows antiviral effects in patients with chronichepatitis C. Presented at the 44 th Annual Meetingof the European Association for the Study of theLiver, Copenhagen, Denmark; April 22-26, 2009;abstract # 43.10. Folori A, Capone S, Ruggeri L, et al. A T-cellHCV vaccine eliciting effective immunity againstheterologous virus challenge in chimpanzees.Nat Med 2006; 12:190.11. Elmowalid GA, Qiao M, Jeong SH, et al.Immunization with hepatitis C virus-like particlesresults in control of hepatitis C virus infection in12.13.14.15.16.chimpanzees. Proc Natl Acad Sci U S A 2007;104:8427.Seeff LB, Curto TM, Szabo G, et al. Herbalproduct use by persons enrolled in the hepatitisC antiviral long-term treatment against cirrhosis(HALT-C) Trial. Hepatology 2008; 47:605.Liu J, Manheimer E, Tsutani K, Gluud C. Medicinalherbs for hepatitis C virus infection: a Cochranehepatobiliary systematic review of randomizedtrials. Am J Gastroenterol 2003; 98: 538.Polyak SJ, Morishima C, Shuhart H, et al.Inhibition of T-cell inflammatory cytokines,hepatocyte NF-KappaB signaling, and HCVinfection by standardized Silymarin.Gastroenterology 2007; 132: 1925.Ferenci P, Screzer TM, Kerschner H, et al.Silibinin is a potent antiviral agent in patients withchronic hepatitis C not responding to pegylatedinterferon/ribavirin therapy. Gastroenterology2008; 135:1561.Herrera J. Treatment of Hepatitis C in thePre-DAA’s Era: treat Now or wait for NewMedications? Practical gastroenterology 2010; 6:13-19.ADVERTISEYOUR PRACTICEin the West Virginia Medical Journal’sProfessional Directory SectionEach physician or group practice space can be upto 2" and includes the information you choose,under the specialty you designate for thenominal fee of $200 per year.Each additional inch is only $100 per year!For more information, contact Angie Lanham,Managing Editor, West VirginiaMedical Journal.304.925.0342, ext. 20 or email yourlisting and billing information toangie@wvsma.com24 West Virginia Medical Journal